CDK4 and sarcoma: Indeed, presence of multiple alterations in different steps of cell cycle regulation might provide primary/secondary resistance mechanisms to CDK inhibition; moreover, when present, CDK4 amplification is the main oncogenic driver of only a subset of CDK4-amplified sarcomas.